Literature DB >> 28604385

Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.

Catherine Matte-Martone1, Jinling Liu2, Meng Zhou2, Maria Chikina3, Douglas R Green4, John T Harty5,6, Warren D Shlomchik2,5,6.   

Abstract

The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (alloSCT) is potent against chronic phase chronic myelogenous leukemia (CP-CML), but blast crisis CML (BC-CML) and acute myeloid leukemias (AML) are GVL resistant. To understand GVL resistance, we studied GVL against mouse models of CP-CML, BC-CML, and AML generated by the transduction of mouse BM with fusion cDNAs derived from human leukemias. Prior work has shown that CD4+ T cell-mediated GVL against CP-CML and BC-CML required intact leukemia MHCII; however, stem cells from both leukemias were MHCII negative. Here, we show that CP-CML, BC-CML, and AML stem cells upregulate MHCII in alloSCT recipients. Using gene-deficient leukemias, we determined that BC-CML and AML MHC upregulation required IFN-γ stimulation, whereas CP-CML MHC upregulation was independent of both the IFN-γ receptor (IFN-γR) and the IFN-α/β receptor IFNAR1. Importantly, IFN-γR-deficient BC-CML and AML were completely resistant to CD4- and CD8-mediated GVL, whereas IFN-γR/IFNAR1 double-deficient CP-CML was fully GVL sensitive. Mouse AML and BC-CML stem cells were MHCI+ without IFN-γ stimulation, suggesting that IFN-γ sensitizes these leukemias to T cell killing by mechanisms other than MHC upregulation. Our studies identify the requirement of IFN-γ stimulation as a mechanism for BC-CML and AML GVL resistance, whereas independence from IFN-γ renders CP-CML more GVL sensitive, even with a lower-level alloimmune response.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28604385      PMCID: PMC5490746          DOI: 10.1172/JCI85736

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  65 in total

Review 1.  Leukaemia stem cells and the evolution of cancer-stem-cell research.

Authors:  Brian J P Huntly; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

2.  NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15).

Authors:  T Nakamura; Y Yamazaki; Y Hatano; I Miura
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

3.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 5.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

6.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.

Authors:  Ahmet H Elmaagacli; Nina K Steckel; Michael Koldehoff; Yael Hegerfeldt; Rudolf Trenschel; Markus Ditschkowski; Sandra Christoph; Tanja Gromke; Lambros Kordelas; Hellmut D Ottinger; Rudolf S Ross; Peter A Horn; Susanne Schnittger; Dietrich W Beelen
Journal:  Blood       Date:  2011-05-03       Impact factor: 22.113

7.  RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3.

Authors:  Christopher P Dillon; Ricardo Weinlich; Diego A Rodriguez; James G Cripps; Giovanni Quarato; Prajwal Gurung; Katherine C Verbist; Taylor L Brewer; Fabien Llambi; Yi-Nan Gong; Laura J Janke; Michelle A Kelliher; Thirumala-Devi Kanneganti; Douglas R Green
Journal:  Cell       Date:  2014-05-08       Impact factor: 41.582

8.  Circulating interferon in cytomegalovirus infected bone-marrow-transplant recipients and in infants with congenital cytomegalovirus disease.

Authors:  A Rhodes-Feuillette; M Canivet; H Champsaur; E Gluckman; M C Mazeron; J Peries
Journal:  J Interferon Res       Date:  1992-05

9.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

10.  Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

Authors:  Sarah J Neering; Timothy Bushnell; Selcuk Sozer; John Ashton; Randall M Rossi; Pin-Yi Wang; Deborah R Bell; David Heinrich; Andrea Bottaro; Craig T Jordan
Journal:  Blood       Date:  2007-06-29       Impact factor: 22.113

View more
  10 in total

Review 1.  The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.

Authors:  Motoko Koyama; Geoffrey R Hill
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

2.  C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells.

Authors:  Asumi Yokota; Hideyo Hirai; Ryuichi Sato; Hiroko Adachi; Fumiko Sato; Yoshihiro Hayashi; Atsushi Sato; Naoka Kamio; Yasuo Miura; Masakazu Nakano; Daniel G Tenen; Shinya Kimura; Kei Tashiro; Taira Maekawa
Journal:  Blood Adv       Date:  2019-02-12

3.  From drug repositioning to target repositioning: prediction of therapeutic targets using genetically perturbed transcriptomic signatures.

Authors:  Satoko Namba; Michio Iwata; Yoshihiro Yamanishi
Journal:  Bioinformatics       Date:  2022-06-24       Impact factor: 6.931

Review 4.  Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.

Authors:  Bruce R Blazar; Geoffrey R Hill; William J Murphy
Journal:  Nat Rev Clin Oncol       Date:  2020-04-20       Impact factor: 66.675

5.  Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.

Authors:  Huidong Guo; Ying-Jun Chang; Yan Hong; Lan-Ping Xu; Yu Wang; Xiao-Hui Zhang; Ming Wang; Huan Chen; Yu-Hong Chen; Feng-Rong Wang; Yu-Qian Sun; Chen-Hua Yan; Fei-Fei Tang; Xiao-Dong Mo; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Cell Mol Immunol       Date:  2021-01-06       Impact factor: 11.530

Review 6.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors:  Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

7.  USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis.

Authors:  Min Li; Yanqin Xu; Jie Liang; Hao Lin; Xinyue Qi; Fanlin Li; Ping Han; Yanfeng Gao; Xuanming Yang
Journal:  Mol Ther       Date:  2021-02-15       Impact factor: 12.910

8.  ATG5-Dependent Autophagy Uncouples T-cell Proliferative and Effector Functions and Separates Graft-versus-Host Disease from Graft-versus-Leukemia.

Authors:  Katherine Oravecz-Wilson; Corinne Rossi; Cynthia Zajac; Yaping Sun; Lu Li; Thomas Decoville; Hideaki Fujiwara; Stephanie Kim; Daniel Peltier; Pavan Reddy
Journal:  Cancer Res       Date:  2020-12-04       Impact factor: 13.312

Review 9.  H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.

Authors:  Eun Young Choi; Kyungho Choi; Giri Nam; Woojin Kim; Minho Chung
Journal:  Front Immunol       Date:  2020-06-10       Impact factor: 7.561

10.  Granzyme A-producing T helper cells are critical for acute graft-versus-host disease.

Authors:  Sungtae Park; Brad Griesenauer; Hua Jiang; Djamilatou Adom; Pegah Mehrpouya-Bahrami; Srishti Chakravorty; Majid Kazemian; Tanbeena Imam; Rajneesh Srivastava; Tristan A Hayes; Julian Pardo; Sarath Chandra Janga; Sophie Paczesny; Mark H Kaplan; Matthew R Olson
Journal:  JCI Insight       Date:  2020-09-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.